| Autor: |
Arranz-Pasqual, N., Torrent-Rodríguez, A., Miana-Mena, M.T., López-Suñé, E., Corominas-García, N., Blanco, I., Soy-Muner, D. |
| Předmět: |
|
| Zdroj: |
Hospital Pharmacy; Oct2024, Vol. 59 Issue 5, p532-535, 4p |
| Abstrakt: |
Ferric carboxymaltose (FCM) allows for rapid and total correction of iron deficiency with a lower risk of hypersensitivity reactions compared to other IV iron preparations. However, FCM is associated with potentially serious adverse events, including hypophosphatemia, following the infusion. The mechanism behind FCM-induced hypophosphatemia is not well understood, but pre-existing risk factors can increase the likelihood of severe and persistent hypophosphatemia. We report a clinical case of a male patient who developed severe hypophosphatemia (1.0 mg/dL) after administration of FCM for the treatment of post-cardiotomy normocytic anemia. He required hospital admission and 16 weeks of phosphorous supplementation. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
